ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline

References

• Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400:1363–80.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S, et al. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry. 2016;87:851–8.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994; 330:585–91.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole Study Group II. Lancet. 1996; 347:1425–31.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15:610–7.
   PubMed Web of Science ®Google Scholar
• Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16:505–12.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020; 383:919–30.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021; 63:31–9.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Hendrix S, Dickson SP, Knowlton N, Berry JD, Elliott MA, et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry. 2022; 93:871–5.
   PubMed Web of Science ®Google Scholar
• Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1-2 Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020; 383:109–19.
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022; 387:1099–110.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014; 13:1127–38.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, de Jongh AD, Nikolakopoulos S, McDermott CJ, Eijkemans MJC, Roes KCB, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021; 22:300–7.
   PubMed Web of Science ®Google Scholar
• Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral Sclerosis: a randomized clinical trial. JAMA Neurol. 2022; 79:575–83.
   PubMed Web of Science ®Google Scholar
• Aizawa H, Kato H, Oba K, et al. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol. 2022; 269:885–96.
   Google Scholar
• Aoki M, Warita H, Kato M, et al. Application of hepatocyte growth factor for amyotrophic lateral sclerosis. Brain Nerve 2019; 71:1253–60.
   PubMedGoogle Scholar
• Morimoto S, Takahashi S, Fukushima K, Saya H, Suzuki N, Aoki M, et al. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regen Ther. 2019; 11:143–66.
   PubMed Web of Science ®Google Scholar
• Imamura K, Izumi Y, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial. EClinicalMedicine 2022; 53:101707.
   PubMedGoogle Scholar
• Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006; 66:265–7.
   PubMed Web of Science ®Google Scholar
• Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B, et al. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008; 275:69–73.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 16:230–6.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Atsuta N, Watanabe H, Hirakawa A, Watanabe H, Ito M, et al. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2013; 84:1365–71.
   PubMed Web of Science ®Google Scholar
• Thakore NJ, Lapin BR, Pioro EP,. Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. 2018; 57:937–45.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy D, Severson K, Ghosh S, Sachs K, Glass JD, Fournier CN, et al. Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data. Nat Comput Sci. 2022; 2:605–16.
   PubMedGoogle Scholar
• Yokoi D, Atsuta N, Watanabe H, Nakamura R, Hirakawa A, Ito M, et al. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. J Neurol. 2016; 263:1129–36.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Atsuta N, Yokoi D, Nakamura R, Nakatochi M, Katsuno M, et al. Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. J Neurol Neurosurg Psychiatry. 2020; 91:285–90.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Tohnai G, Nakatochi M, Atsuta N, Watanabe H, Ito D, et al. Genetic factors affecting survival in Japanese patients with sporadic amyotrophic lateral sclerosis: a genome-wide association study and verification in iPSC-derived motor neurons from patients. J Neurol Neurosurg Psychiatry. 2023;94:816–24. jnnp-2022-330851. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014; 83:1719–25.
   PubMed Web of Science ®Google Scholar
• Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15:406–13.
   PubMed Web of Science ®Google Scholar
• EDARAVONE (MCI-186) ALS 16 STUDY GROUP A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18:11–9.
   PubMed Web of Science ®Google Scholar
• Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020; 21:5–14.
   PubMed Web of Science ®Google Scholar
• Haji S, Fujita K, Oki R, Osaki Y, Miyamoto R, Morino H, et al. An exploratory trial of EPI-589 in amyotrophic lateral sclerosis (EPIC-ALS): protocol for a multicenter, open-labeled, 24-week, single-group study. JMIR Res Protoc. 2023;12:e42032.
   PubMed Web of Science ®Google Scholar